Nutriband Inc. (NTRB)
7.69
-0.27 (-3.39%)
At close: Jan 28, 2025, 2:17 PM
undefined% (undefined)
| Bid | 7.55 |
| Market Cap | 85.42M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -10.83 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.7 |
| Volume | 105,602 |
| Avg. Volume (20D) | 161,913 |
| Open | 8.07 |
| Previous Close | 7.96 |
| Day's Range | 7.25 - 8.07 |
| 52-Week Range | 2.22 - 11.78 |
| Beta | undefined |
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; e...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol NTRB
Website https://nutriband.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NTRB stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 69.03% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
5 days ago
+40.88%
Nutriband shares are trading higher after Noble Ca...
Unlock content with
Pro Subscription
10 months ago
+33.22%
Nutriband shares are trading higher after the company provided a clinical and regulatory path overview for its AVERSA Fentanyl patch.